Keros Therapeutics (NASDAQ:KROS) VP Annita Tanini Sells 1,224 Shares of Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) VP Annita Tanini sold 1,224 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total transaction of $12,594.96. Following the sale, the vice president directly owned 45,144 shares in the company, valued at $464,531.76. This represents a 2.64% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Keros Therapeutics Stock Performance

NASDAQ KROS opened at $10.95 on Friday. The firm has a market cap of $217.11 million, a price-to-earnings ratio of -2.96 and a beta of 0.99. The firm has a 50 day simple moving average of $10.69 and a 200-day simple moving average of $11.85. Keros Therapeutics, Inc. has a one year low of $9.69 and a one year high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. Equities analysts predict that Keros Therapeutics, Inc. will post -5.16 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Zacks Research cut Keros Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Keros Therapeutics in a report on Wednesday, August 12th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Keros Therapeutics in a research note on Tuesday, August 4th. Wall Street Zen downgraded shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday, August 16th. Finally, Leerink Partners decreased their price objective on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a research report on Tuesday, August 4th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $20.50.

Institutional Investors Weigh In On Keros Therapeutics

Several institutional investors have recently added to or reduced their stakes in KROS. AQR Capital Management LLC purchased a new position in shares of Keros Therapeutics in the 1st quarter valued at $226,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Keros Therapeutics by 15.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,166 shares of the company’s stock valued at $227,000 after acquiring an additional 2,982 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Keros Therapeutics by 38.3% in the first quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock valued at $7,547,000 after acquiring an additional 205,022 shares in the last quarter. Creative Planning grew its holdings in shares of Keros Therapeutics by 40.2% during the second quarter. Creative Planning now owns 24,226 shares of the company’s stock worth $323,000 after purchasing an additional 6,948 shares during the last quarter. Finally, Rhumbline Advisers grew its holdings in shares of Keros Therapeutics by 16.0% during the second quarter. Rhumbline Advisers now owns 51,815 shares of the company’s stock worth $692,000 after purchasing an additional 7,146 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.